Skip to main content
MIT Corporate Relations
MIT Corporate Relations
Search
×
Read
Watch
Attend
About
Connect
MIT Startup Exchange
Search
Sign-In
Register
Search
×
MIT ILP Home
Read
Faculty Features
Research
News
Watch
Attend
Conferences
Webinars
Learning Opportunities
About
Membership
Staff
For Faculty
Connect
Faculty/Researchers
Program Directors
ILP Members
MIT Startup Exchange
User Menu and Search
Search
Sign-In
Register
MIT ILP Home
Toggle menu
Search
Sign-in
Register
Read
Faculty Features
Research
News
Watch
Attend
Conferences
Webinars
Learning Opportunities
About
Membership
Staff
For Faculty
Connect
Faculty/Researchers
Program Directors
ILP Members
MIT Startup Exchange
Back to Faculty/Researchers
Prof. Donald E Ingber
Judah Folkman Professor of Vascular Biology
Judah Folkman Professor of Vascular Biology, Surgery, Boston Children's Hospital and Harvard Medical School (HMS)
Professor of Bioengineering, Harvard School of Engineering & Applied Science
Director, Wyss Institute
MIT Room:
HARVARD-3 BLAC
(617) 355-8031
don.ingber@wyss.harvard.edu
http://hst.mit.edu/faculty-research/faculty/ingber-donald
Assistant
Jeanne Nisbet
jeanne.nisbet@childrens.harvard.edu
Areas of Interest and Expertise
Mechanical Stress
Cytoskeleton
Cellular Mechanotransduction
Extracellular Matrix
Focal Adhesions
Experimental Mammary Neoplasms
Mesenteric Vascular Occlusion
Tensile Strength
Research Summary
Donald Ingber is interested in how cell structure and mechanics impact cellular biochemistry and tissue development.?? His research approach has combined techniques from various fields, including molecular cell biology, engineering, chemistry, physics, and computer science.
Ingber's angiogenesis research focuses on how the shape of a vascular blood vessel cell and the physical properties of its environment influence whether the cell grows, produces specialized products, moves, or dies. Through these efforts, Ingber has made pioneering contributions to the fields of angiogenesis, tissue engineering, mechanobiology, and systems biology. His work on how blood vessels form also led to the development of TNP-470, one of the first angiogenesis inhibitors to enter clinical trials.
Recent Work